Gary Reedy has a big turnaround project on his hands.
The Roche-Syapse collaboration to develop analytics programs may enable health systems to measure the impact of precision therapies, said Damon Hostin, CEO of the Precision Medicine Alliance.
Syapse and Roche are working on building software that would allow health systems to incorporate real-world evidence into Syapse's platform in an effort to develop true clinical decision support for precision therapies.
Lefkofsky spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
Hudis spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
After 20 years at Ohio State University, Michael Caligiuri is moving on.
Trying to build a cancer center in the middle of a saturated market should be difficult enough.
With a month to go before his Dec. 1 start date as president of MD Anderson Cancer Center, Peter Pisters reflected on the challenges that await him in Houston.
Ten years ago, the formation of the Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center was met with skepticism.
When Eric Karlson's lymphoma went into complete regression in 2009, Steven Rosenberg and James Kochenderfer knew they were making history—for the first time, they had cured a patient by using genetically modified cell therapy, specifically, anti-CD19 CAR-T cells.
